Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement

Executive Summary

FDA says it likely will oppose the provision because it would create more administrative complexity and increase fees paid by individual firms, but many provider and professional associations think waivers could help prevent and alleviate drug shortages.

You may also be interested in...



GDUFA Negotiations Shift To 'Tiered' Fee Models

Finance subgroup talks about new structure for generic drug user fee program that could mean bigger firms would pay more.

GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’

Negotiations for generic drug user fee reauthorization open with FDA saying it doesn't want a large number of small tweaks that will increase program complexity.

Generic User Fees Might Get Brand-Style Exemptions

GPhA and other stakeholders may propose changes to the GDUFA user fee structure amid small business complaints about burden of facility fees.

Related Content

Topics

UsernamePublicRestriction

Register

PS054285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel